1,200
Participants
Start Date
September 15, 2015
Primary Completion Date
August 31, 2016
Study Completion Date
August 31, 2016
1-dose cIPV + 2-doses bOPV (Candy)
Health subjects received 1-dose cIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Candy) through mouth at 0, 28, 56 days schedule.
1-dose sIPV + 2-doses bOPV (Candy)
Health subjects received 1-dose sIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Candy) through mouth at 0, 28, 56 days schedule.
2-doses cIPV + 1-dose bOPV (Candy)
Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Candy) through mouth at 0, 28, 56 days schedule.
2-doses sIPV + 1-dose bOPV (Candy)
Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Candy) through mouth at 0, 28, 56 days schedule.
2-doses cIPV + 1-dose tOPV (Candy)
Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Candy) through mouth at 0, 28, 56 days schedule.
2-doses sIPV + 1-dose tOPV (Candy)
Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Candy) through mouth at 0, 28, 56 days schedule.
1-dose cIPV + 2-doses bOPV (Liquid)
Health subjects received 1-dose cIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
1-dose sIPV + 2-doses bOPV (Liquid)
Health subjects received 1-dose sIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
2-doses cIPV + 1-dose bOPV (Liquid)
Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
2-doses sIPV + 1-dose bOPV (Liquid)
Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
2-doses cIPV + 1-dose tOPV (Liquid)
Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Liquid) through mouth at 0, 28, 56 days schedule.
2-doses sIPV + 1-dose tOPV (Liquid)
Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Liquid) through mouth at 0, 28, 56 days schedule.
Guangxi Provincial Center for Diseases Control and Prevention, Nanning
Guangxi Center for Disease Control and Prevention
OTHER_GOV
Institute of Medical Biology, Chinese Academy of Medical Sciences
OTHER